according to washingtonpost
Steelers' DeAngelo Williams hugs breast cancer survivors before game
Steelers' DeAngelo Williams hugs breast cancer survivors before game
DeAngelo Williams is in his second season with the Steelers after nine with the Panthers.(AP Photo/Jared Wickerham)October is Breast Cancer Awareness Month, and the NFL has been taking part for several years, most noticeably by allowing teams to accent their uniforms with the color pink.In terms of actual awareness of breast cancer, perhaps no football player has been more acutely affected as the Steelers' DeAngelo Williams, who lost his mother and her four sisters to it.[Williams outs himself as 'a Nickelback fan']So when his team hosted several breast cancer survivors before its game against the Jets on Sunday, Williams wasn't about to miss an opportunity to share a moment with the women.
additionally siasat
Targeting estrogen receptor increases progression-free survival in advanced breast cancer
Targeting estrogen receptor increases progression-free survival in advanced breast cancer
Washington D.C.[USA]: Fulvestrant significantly increases progression-free survival in women with positive advanced breast cancer, particularly those with less aggressive lower-volume disease, reports a recent research.Fulvestrant is a selective estrogen receptor degrader that targets the function of the hormone receptor so, unlike aromatase inhibitors such as anastrozole, it does not interfere with estrogen levels themselves.The randomized, double-blind, multi-center phase III trial enrolled 462 women with inoperable locally-advanced or metastatic ER-positive, HER-negative breast cancer, who had not received prior hormone therapy.Half the patients (n=230) were randomized to 500mg intramuscular injections of fulvestrant (Days 0, 14, 28, then every 28 days), or to 1mg of anastrozole daily (n=232), and were also allowed one line of chemotherapy.
in addition dailyprogress
Health: Crowdsourcing boosts metastatic breast cancer research
Health: Crowdsourcing boosts metastatic breast cancer research
Sorry, this zipcode is not in our deliverable area for this subscription service.Re-enter zip code or sign up for digital access.Get digital access
not to mention news-medical
Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients
Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.The first interim analysis of data from the randomized, double-blind MONALEESA study showed a 44% improvement in progression-free survival with ribociclib plus letrozole as a first-line treatment combination."This was THE definitive study to demonstrate the superiority of the combination of ribociclib and letrozole over letrozole alone," said principle investigator, Professor Gabriel Hortobagyi, from the University of Texas MD Anderson Cancer Center in Houston, Texas, US.Researchers randomized 668 postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, who had not undergone any prior systemic treatment, to ribociclib (600 mg/day, 3 weeks on/1 week off) and letrozole (2.5 mg/day, continuous), or letrozole plus placebo.
No comments:
Post a Comment